Index to Volume Thirteen

Index of Issues: January–March 1–60; April–June 61–118; July–September 119–178; Supplement 179–206; October–December 207–268.

INDEX OF AUTHORS

A

Adams MR, 221
Aine R, 5
Al-Harmozi SA, 102
Albritton WL, 145
Alpert S, 67
Aznar J, 169

B

Baker-Zander SA, 9, 185, 214
Batchelor RA, 47
Baxter RP, 174
Becker TM, 88
Benes S, 105
Biberfeld G, 111
Biddle JW, 47
Blakley KG, 47
Blount JH, 88
Boggs D, 138
Bowie WR, 159
Bowie WR, 76
Bowmer I, 189
Brunham RC, 53
Burdge DR, 159
Bygdeman S, 111

C

Cates W, Jr, 114
Catlin BW, 29, 133
Chow AW, 159
Cockayne A, 237
Cole B, 163
Conwill DE, 47
Coopes S, 108
Crockett VA, 67
Cummings M, 105

D

D'Costa LJ, 53, 166, 189
Daling JR, 16
Davidson AJ, 97
De Jong AR, 123
De Miguel C, 169
Dhamu F, 156
Douglas J, 88
Dylewski J, 166, 189

E

Edmondson DG, 207
El-Tonsy MH, 102
England EH, 108
Evrard JR, 67

F

Faro S, 81, 174
Farshy CE, 221, 228, 232
Feeley JC, 228
Felman Y, 105
Fife KH, 138
Fiumara NJ, 45
Fortenberry JD, 172
Fransen L, 53, 189

G

Givan KF, 19
Gottlieb AB, 151, 203
Graman PS, 50
Greisberger C, 50
Gronroos P, 5

H

Haase DA, 53
Hambie EA, 221
Handsfield HH, 179, 185, 214
Harris JRW, 93
Harris ON, 245
Harrison WO, 203
Heinonen PK, 5
Hernandez I, 169
Hindersson P, 237
Hoffman L, 174
Hook EW III, 185
Howell HB, 47
Hunter EF, 228, 232

J

Jaeger R, 19
Jansson E, 24
Jones HD, 76
Judson FN, 88, 97, 119, 199

K

Kappus EW, 134
Kessock-Philip S, 93

L

Laine S, 5
Lake J, 47
Lakeman AD, 61
Larsen SA, 221, 228, 232
Latif AS, 156
Liu H, 245
Lukehart SA, 9, 185, 214

M

Marowa E, 156
Martin D, 71, 81
Martin R, 108
Mason PR, 156
Mathieu LG, 71
McCormack WM, 67, 105, 258
McNicol PJ, 145
Menegus MA, 50
Michel MF, 1
Miettinen A, 24
Mills J, 151, 203
Moskovitz BL, 185

N

Nahmias AJ, 61
Nash RA, 53
Nayyar KC, 105
Neagle P, 108
Nemeth A, 111
Norris SJ, 207
Nsanze H, 53, 166, 189

P

Paavonen J, 5, 24
Pace PJ, 29, 133
Paraiwa E, 156
Parkash S, 127
Pastorek JG, II, 81
Pender BJ, 221
Perea EJ, 169
Pettit DE, 221
Phillips LE, 174
Piot P, 53, 189
Plummer FA, 189
Pon E, 47
Pope V, 228
Prados R, 169

Q

Quinn TC, 134

R

Radhakrishna K, 127
Reichman RC, 50
Rice RJ, 47
Roddy RE, 214
Rodriguez-Pichardo A, 169
Romanowski B, 93
Ronald AR, 145, 166, 189
Rosner B, 67
Russell H, 232

S

Saikku P, 24
Sampson JS, 232
Sandstrom E, 111
Schachter J, 40
Schell RF, 245
Schouls LM, 237
Scott BD, 172
Sell S, 9
Sherman KJ, 16
Singal SS, 50
Sithole J, 156
Slutkin G, 151
Stamm WE, 163
Steiner BM, 245
Stolz E, 1, 105
Sullam PM, 151
Sung ML, 40
Sweet RL, 192
Swenson CE, 40

T

Tambo J, 156
Tang S, 45
Tavelli BG, 119
Trupei MA, 50
Turgeon PL, 71

V

Van Eijk, RVW, 1
Van Emden JDA, 237
Van Joost T, 1
Van Strik R, 1
Van Ulsen J, 1

W

Weber J, 105
Weiss NS, 16
Wentworth BB, 108
Whitley RJ, 61
Wicher K, 251
Wicher V, 251
Wood H, 93
Wos SM, 251

Y

Yu JS, 76

Z

Zinner SH, 67

INDEX OF SUBJECTS

A

Acquired immune deficiency syndrome, early pediatric case from Zaire (Nemeth & others), 111
Acyclovir, for herpetic hepatitis, in nonpregnant patient (Baxter & others), 174
Amebiasis, endemic, in male homosexuals, paramomycin therapy for (Sullam & others), 151
Amebic ulcer, chronic intractable, surgery of (Parkash & Radhakrishna), 127
Ampicillin, plasmid-mediated resistance to, interspecies transfer of (McNichol; Albritton & Ronald), 145
Anorectal gonorrhea, in women (Davidson & Judson), 97
Antibiotic resistance of *N. gonorrhoeae* isolates (Pace & Catlin), 29 (Erratum, 133)
Antibiotics,
  β-lactam,
    for bacterial sexually transmitted diseases (Handsfield), 179
    for *C. trachomatis* (Martin; Pastorek & Faro), 81
    for gonorrhea (Mills; Gottleib & Harrison), 203
Antigens, of *Treponema pallidum,* rabbit humoral immune response to (Lukehart; Baker-Zander & Sell), 9

B

Bacterial sexually transmitted diseases, treatment problems in (Handsfield), 179
Balanoposthitis, *Gardnerella vaginalis*-associated (Burdge; Bowie & Chow), 159
Beta-lactam antibiotics. *See* β-Lactam antibiotics
Buttocks, folliculitis of, and pinworms (Fiumara & Tang), 45

C

C3, depletion of, and resistance to yaws (Steiner & others), 245
Ceftriaxone
  for asymptomatic neurosyphilis (Hook), 185
  for bacterial sexually transmitted diseases (Handsfield), 179
  for gonorrhea (Judson), 199
  single-case, for gonococcal ophthalmia neonatorum (Haase & others), 53
Cephalosporins
  for *C. trachomatis* (Martin; Pastorek & Faro), 81
  for gonorrhea (Mills; Gottlieb & Harrison), 203
Chancroid
  diagnosis and management of (D'Costa & others), 189
  single-dose trimethoprim-sulfametrole for, (Dylewski & others), 166
  treatment problems in (Handsfield), 179
Child(ren)
  early case of AIDS in, in Zaire (Nemeth), 111
  sexually abused, sexually transmitted diseases in (De Jong), 123
Chlamydia trachomatis
  β-lactam antibiotics for (Martin; Pastorek & Faro), 81
  clindamycin for, in men with nongonococcal urethritis (Bowie, Yu & Jones), 76
  isolation of from men with urethritis (Singal & others), 50
  spermicidal inhibition of (Kappus & Quinn), 134
Chlamydial infections, treatment problems in (Handsfield), 179
Chlamydial pelvic inflammatory disease associated with, epidemiologic and clinical characteristics of (Miettinen & others), 24
Chlamydial postgonococcal conjunctivitis (Scott & Fortenberry), 172
Chlamydial salpingitis, and tetracycline (Swenson; Sung & Schachter), 40
Chlamydial urethritis
  in men
    asymptomatic (Stamm & Cole), 163
    clindamycin for (Bowie; Yu & Jones), 76
    isolation of *C. trachomatis* in (Singal & others), 50
Ciprofloxacin, single-dose, for gonorrhea (Aznar & others), 169
Clindamycin
  for C. trachomatis (Martin; Pastorek & Faro), 81
    in men with nongonococcal urethritis (Bowie; Yu & Jones), 76
Condyloma acuminatum, risk factors for, in women (Daling; Sherman & Weiss), 16
Conjunctivitis, postgonococcal, due to *C. trachomatis* (Scott & Fortenberry), 172
Contraceptives, oral, and condyloma acuminatum, in women (Daling; Sherman & Weiss), 16

D

DNA, from recurrent genital herpes simplex virus isolates, restriction endonuclease digestion analysis of (Lakeman; Nahmias & Whitley), 61

E

Enzyme-linked immunosorbent assay, specificity of (Farshy & others), 228

F

Fluorescent treponemal antibody-adsorbtion test
  cross-reactivity of Lyme disease and syphilis in (Hunter & others), 232
  specificity of (Farshy & others), 228
  staining intensities in (Larsen & others), 221
Folliculitis, of buttocks, and pinworms (Fiumara & Tang), 45

G

Gardnerella vaginalis-associated balanoposthitis (Burdge; Bowie & Chow), 159
Genital herpes simplex virus, recurrent, isolates of, restriction endonuclease digestion analysis of (Lakeman; Nahmias & Whitley), 61
Genital pathogens, in prostitutes in New York and Rotterdam (Nayyar & others), 105
Gonococcal ophthalmia neonatorum, single-dose ceftriaxone for (Haase & others), 53
Gonococcal pelvic inflammatory disease, *vs.* nongonococcal PID, clinical and epidemiologic characteristics of, 119
Gonorrhea. *See also Neisseria gonorrhoeae*
  anorectal, in women (Davidson & Judson), 97
  ceftriaxone for (Judson), 199
  cephalosporins and β-lactam antibiotics for (Mills; Gottlieb & Harrison), 203
  detection of, in prostitutes, enzyme immunoassay for (Van Ulsen & others), 1
  diagnosis of, Thayer-Martin *vs.* Transgrow *vs.* Gonozyme for (Martin & others), 108

oral thiamphenicol and lymecycline for (Latif & others), 156
resistant to spectinomycin (Pon & others), 47
single-dose ciprofloxacin for (Aznar & others), 169
treatment problems in (Handsfield), 179
in women, improved diagnosis of (Romanowski & others), 93
Gonozyme test, *vs.* Transgrow and Thayer-Martin cultures, in gonorrhea diagnosis (Martin & others), 108
Granuloma inguinale
chronic intractable, surgery of (Parkash & Radhakrishna), 127
in Qatar (Al-Harmozi & El-Tonsy), 102

H

Haemophilus spp., plasmid-mediated ampicillin resistance of, transfer of to *N. gonorrhoeae* (McNichol; Albritton & Ronald), 145
Hepatitis, herpetic, in nonpregnant patient, acyclovir for (Baxter & others), 174
Herpes simplex virus 1, recurrent infection with, intertypic recombinants and (Fife & Boggs), 138
Herpetic hepatitis, in nonpregnant patient, acyclovir for (Baxter & others), 174
Homosexual(s)
male
endemic amebiasis in, paromomycin therapy for (Sullam & others), 151
N. gonorrhoeae auxotypes from (Givan & Jaeger), 24

I

Immunoassay, modified solid-phase enzyme, for gonorrhea detection, in prostitutes (Van Ulsen & others), 1
Immunofluorescence assay, specificity of (Farshy & others), 228
Infertility, after chlamydial salpingitis, and tetracycline (Swenson; Sung & Schachter), 40

L

β-Lactam antibiotics
for bacterial sexually transmitted diseases (Handsfield), 179
for *C. trachomatis* (Martin; Pastorek & Faro), 81
for gonorrhea (Mills; Gottlieb & Harrison), 203
Lyme disease, and syphilis, cross-reactivity of in FTA-Abs test (Hunter & others), 232
Lymecycline, and thiamphenicol, for gonorrhea (Latif & others), 156
Lymphogranuloma venereum, chronic intractable, surgery of (Parkash & Radhakrishna), 127

M

Mezlocillin, for *C. trachomatis* (Martin; Pastorek & Faro), 81
Microhemagglutination *Treponema pallidum* test, specificity of (Farshy & others), 228
Molluscum contagiosum, in the U.S. (1966–1983) (Becker & others), 88
Mycoplasma hominis
pelvic inflammatory disease associated with, epidemiologic and clinical characteristics of (Miettinen & others), 24
vaginal colonization with, risk factors in (McCormack & others), 67

N

Neisseria gonorrhoeae. See also Gonorrhea
isolates of
antibiotic responses and nutritional requirements of (Pace & Catlin), 29 (Erratum, 133)
auxotypes of (Givan & Jaeger), 19
molecular weight of envelope protein 1 and colony opacity of (Martin; Turgeon & Mathieu), 71
pelvic inflammatory disease associated with, epidemiologic and clinical characteristics of (Miettinen & others), 24
penicillinase-producing, resistant to spectinomycin (Pon & others), 47
plasmid-mediated ampicillin resistance of, from *Haemophilus spp.* (McNichol; Albritton & Ronald), 145
Neurosyphilis, asymptomatic, ceftriaxone for (Hook & others), 185
Nongonococcal pelvic inflammatory disease, *vs.* gonococcal PID, clinical and epidemiologic characteristics of (Tavelli & Judson), 119
Nongonococcal urethritis, in men, *C. trachomatis* in, clindamycin for (Bowie; Yu & Jones), 76
Nonoxynol-9, inhibition of *C. trachomatis* by (Kappus & Quinn), 134

O

Ophthalmia neonatorum, gonococcal, single-dose ceftriaxone for (Haase & others), 53
Oral contraceptives, and condyloma acuminatum (Daling; Sherman & Weiss), 16

P

Paromomycin, for endemic amebiasis, in male homosexuals (Sullam & others), 151
Passing the baton (McCormack; editorial), 258
Pelvic inflammatory disease
associated with *M. hominis, C. trachomatis,* and *N. gonorrhoeae,* epidemiologic and clinical characteristics of (Miettinen & others), 24
gonococcal and nongonococcal, clinical and epidemiologic characteristics of (Tavelli & Judson), 119
prevention, diagnosis, and management of (Sweet), 192
treatment problems in (Handsfield), 179
Pinworms, and folliculitis of buttocks (Fiumara & Tang), 45
Piperacillin, for *C. trachomatis* (Martin; Pastorek & Faro), 81
Postgonococcal conjunctivitis, chlamydial (Scott & Fortenberry), 172
Pregnancy, third-trimester, nonspecific vaginitis in (Paavonen & others), 5
Prostitutes, in New York and Rotterdam, genital pathogens in (Nayyar & others), 105
Pruritus ani, due to pinworms, and folliculitis of buttocks (Fiumara & Tang), 45

Q

Qatar, granuloma inguinale in (Al-Harmozi & El-Tonsy), 102
Quantitative immunofluorescence assay, specificity of (Farshy & others), 228

R

Restriction endonuclease digestion analysis, of DNA from recurrent genital herpes virus (Lakeman; Nahmias & Whitley), 61

S

Salpingitis, chlamydial, and tetracycline (Swenson; Sung & Schachter), 40
Sexual abuse, of children, and sexually transmitted diseases (De Jong), 123
Sexually transmitted diseases
bacterial, treatment problems in (Handsfield), 179
current and future priorities for (Cates; editorial), 114
in sexually abused children (De Jong), 123

Spectinomycin, penicillinase-producing *N. gonorrhoeae* resistant to (Pon & others), 47
Spermicide Nonoxynol-9, inhibition of *C. trachomatis* by (Kappus & Quinn), 134
Sulfametrole. *See* Trimethoprim-sulfametrole
Syphilis
  FTA-Abs test for, staining intensities in (Larsen & others), 221
  and Lyme disease, cross-reactivity of in FTA-Abs test (Hunter & others), 232
  pathogenic and nonpathogenic treponemes in, cross-reactivity of (Wicher; Wos & Wicher), 251
  serologic tests, for specificity of (Farshy & others), 228
  treatment of
    IgG and IgM reactivity to *T. pallidum* after, (Baker-Zander & others), 214
    problems in (Handsfield), 179

T

Tetracycline, and chlamydial salpingitis (Swenson; Sung & Schachter), 40
Thayer-Martin cultures. *vs.* Transgrow and Gonozyme, in gonorrhea diagnosis (Martin & others), 108
Thiamphenicol, and lymecycline, for gonorrhea (Latif & others), 156
Ticarcillin, for *C. trachomatis* (Martin; Pastorek & Faro), 81
Transgrow culture, *vs.* Transgrow and Gonozyme, in gonorrhea diagnosis (Martin & others) 108
Treponema pallidum
  antigne(s) of
    IgG and IgM reactivity to, post-treatment (Baker-Zander & others), 214
    rabbit humoral immune response to (Lukehart; Baker-Zander & Sell), 9
    TpD of, as expressed by *E. coli* K12 (Hindersson & others), 237
  and nonpathogenic treponemes, cross-reactivity of (Wicher; Wos & Wicher), 251
  serum requirement for multiplication of (Norris & Edmondson), 207
Treponema pallidum immobilization test, specificity of (Farshy & others), 228
Treponema pallidum subspecies *pertenue*, resistance to, and C3 depletion (Steiner & others), 245
Trimethoprim-sulfametrole, single-dose, for female chancroid, (Dylewski & others), 166

U

Ulcerative lesions, chronic intractable, surgery of (Parkash & Radhakrishna), 127
Ureaplasma urealyticum, vaginal colonization with, risk of factors in (McCormack & others), 67
Urethritis
  in men
    nongonococcal chlamydial
      asymptomatic (Stamm & Cole), 163
      clindamycin for (Bowie; Yu & Jones), 76
      isolation of *C. trachomatis* in (Singal & others), 50

V

Vagina, colonization of with *M. hominis* and *U. urealyticum*, risk factors in (McCormack & others), 67
Vaginitis, nonspecific, in third-trimester pregnancy (Paavonen & others), 5

Y

Yaws, resistance to, and C3 depletion (Steiner & others), 245

Z

Zaire, early case of pediatric AIDS in (Nemeth & others), 111

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Required by 39 U.S.C. 3685)

Date of Filing—October 1, 1986
Title of Publication—Sexually Transmitted Diseases
Publication No. 371350
Frequency of Issue—Quarterly: Jan–March, April–June, July–Sept, Oct–Dec
Subscription Price—$48.00
Location of Known Office of Publication—2350 Virginia Ave., Hagerstown, MD 21740
Location of the Headquarters of General Business Offices of the Publishers—East Washington Square, Philadelphia, PA 19105
Publisher—American Venereal Disease Association, East Washington Square, Philadelphia, PA 19105
Editor—Michael F. Rein, M.D., University of Virginia Medical School, Box 385, Infectious Diseases Division, Charlottesville, VA 22908
Managing Editor—Ann S. Kishbaugh, East Washington Square, Philadelphia, PA 19105
Owner—American Venereal Disease Association, Box 22349, San Diego, CA 92122
Known Bondholders, Mortgages and Other Security Holders Owning or Holding 1% or More of Total Amount of Bonds, Mortgages or Other Securities—None
The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes has not changed during preceding 12 months.

	Average No. Copies Each Issue during Preceding 12 Months	Actual No. of Copies of Single Issues Published Nearest to Filing Date
A. Total No. Copies Printed (*Net Press Run*)	2,675	2,700
B. Paid Circulation		
1. Sales through dealers and carriers, street vendors and counter sales	—	—
2. Mail Subscription	1,818	1,967
C. Total Paid Circulation	1,818	1,967
D. Free Distribution by Mail, Carrier or Other Means. Samples, Complimentary, and Other Free Copies	61	48
E. Total Distribution (*Sum of C and D*)	1,879	2,015
F. Copies Not Distributed		
1. Office use, left over, unaccounted, spoiled after printing	796	685
2. Return from News Agents	—	—
G. Total (*Sum of E, F1 and 2—should equal net press run shown in A*)	2,675	2,700

I certify that the statements made by me above are correct and complete.
Joseph W. Lippincott III, *Associate Publisher*